Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade
The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced
cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n= 978) …
cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n= 978) …
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with
cancer. However, existing biomarkers do not reliably predict treatment response across …
cancer. However, existing biomarkers do not reliably predict treatment response across …
Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
L Cabel, C Proudhon, E Romano, N Girard… - Nature reviews Clinical …, 2018 - nature.com
Considerable interest surrounds the use of immune-checkpoint inhibitors in patients with
solid tumours following the demonstration of the impressive clinical efficacy of anti …
solid tumours following the demonstration of the impressive clinical efficacy of anti …
Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L) 1 blockade in NSCLC
Abstract Purpose: Treatment with PD-(L) 1 blockade can produce remarkably durable
responses in patients with non–small cell lung cancer (NSCLC). However, a significant …
responses in patients with non–small cell lung cancer (NSCLC). However, a significant …
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
SY Cindy Yang, SC Lien, BX Wang… - Nature …, 2021 - nature.com
Serial circulating tumor DNA (ctDNA) monitoring is emerging as a non-invasive strategy to
predict and monitor immune checkpoint blockade (ICB) therapeutic efficacy across cancer …
predict and monitor immune checkpoint blockade (ICB) therapeutic efficacy across cancer …
Early assessment of lung cancer immunotherapy response via circulating tumor DNA
SB Goldberg, A Narayan, AJ Kole, RH Decker… - Clinical Cancer …, 2018 - AACR
Purpose: Decisions to continue or suspend therapy with immune checkpoint inhibitors are
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …
Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non–small-cell lung cancer treated with immune checkpoint inhibitors
DM Vega, KK Nishimura, N Zariffa… - JCO Precision …, 2022 - ascopubs.org
PURPOSE As immune checkpoint inhibitors (ICI) become increasingly used in frontline
settings, identifying early indicators of response is needed. Recent studies suggest a role for …
settings, identifying early indicators of response is needed. Recent studies suggest a role for …
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
EJ Lipson, VE Velculescu, TS Pritchard… - … for immunotherapy of …, 2014 - Springer
Background Assessment of therapeutic activity of drugs blocking immune checkpoints such
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear …
Current and future clinical applications of ctDNA in immuno-oncology
JC Stadler, Y Belloum, B Deitert, M Sementsov… - Cancer Research, 2022 - AACR
Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …
Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer
Despite the initial successes of immunotherapy, there is an urgent clinical need for
molecular assays that identify patients more likely to respond. Here, we report that …
molecular assays that identify patients more likely to respond. Here, we report that …
相关搜索
- checkpoint blockade tumor dna
- tumor patients predictive biomarker
- checkpoint blockade immune responses
- checkpoint blockade melanoma patients
- lung cancer tumor dna
- immune responses dynamics of tumor
- early assessment tumor dna
- clinical benefit tumor dna
- tumor burden melanoma patients
- checkpoint inhibitors lung cancer
- checkpoint blockade dynamics of tumor
- checkpoint blockade tumor burden
- checkpoint inhibitors tumor dna